

Progression Free Survival	All Patients (34)	Cases	Univariable Cox HR [CI]	p value ¹	Multivariable Cox HR [CI]	p value
Age						
Median, years (range)	34	31	1.02 [0.98-1.05]	0.35	1.00 [0.97-1.04]	0.91
WHO performance score (%)						
0	20	17	1		1	
1, 2 or missing	14	14	1.49 [0.73-3.06]	0.28	1.53 [0.60-3.94]	0.37
LDH (%)						
Normal	18	17	1		1	
Elevated (>250 U/L)	16	14	0.93 [0.45-1.90]	0.83	0.86 [0.41-1.80]	0.68
Brain metastases (%)						
No/ not confirmed	22	21	1		1	
Yes	12	10	0.73 [0.34-1.58]	0.42	0.96 [0.36-2.61]	0.94
Pretreated immunotherapy						
No	14	12	1		1	
Yes	20	19	1.51 [0.72-3.16]	0.27	1.55 [0.66-3.64]	0.31
Absolute leukocyte count before IFNa (x 10⁹/L)						
Median (range)	34	31	1.08 [0.96-1.21]	0.22		
Absolute neutrophil count before IFNa (x 10⁹/L)						
Median (range)	34	31	1.09 [0.96-1.23]	0.19		
Absolute monocyte count before IFNa (x 10⁹/L)						
Median (min-max)	34	31	3.51 [0.80-15.33]	0.10		
Absolute lymphocyte count before IFNa (x 10⁹/L)						
Median (range)	34	31	0.78 [0.43-1.41]	0.41		
Leukocyte/lymphocyte ratio						
Median (min-max)	34	31	1.04 [1.01-1.08]	0.01		
Neutrophil/lymphocyte ratio						
Median (min-max)	34	31	1.04 [1.01-1.08]	0.02		
Monocyte/lymphocyte ratio						
Median (min-max)	34	31	3.03 [1.46-6.26]	0.003	2.84 [1.33-6.09]	0.007

Supplemental Table 5. Uni- and multivariate analysis PFS.

¹ Statistically significant p values are indicated in bold.

In the univariate analysis clinical parameters known to be associated with survival in metastatic melanoma patients were included. From the known (possible) predictors measured in routine blood testing (complete blood count) for response to immunotherapy MLR was selected in the final multivariate model for PFS as it was the strongest predictor for survival in the univariate analysis.